Use of the Quick Dementia Rating System (QDRS) as an Initial Screening Measure in a Longitudinal Cohort at Risk for Alzheimer's Disease
Sara E Berman, Rebecca L Koscik, Lindsay R Clark, Kimberly D Mueller, Lisa Bluder, James E Galvin, Sterling C Johnson, Sara E Berman, Rebecca L Koscik, Lindsay R Clark, Kimberly D Mueller, Lisa Bluder, James E Galvin, Sterling C Johnson
Abstract
The Quick Dementia Rating System (QDRS) and Clinical Dementia Rating Scale (CDR) assess global cognitive and functional decline. We evaluated whether the shorter QDRS was a valid screen for problems identified by the CDR in individuals with minimal clinical abnormalities. Agreement between QDRS-Global and CDR-Global was assessed for 54 participants from the Wisconsin Registry for Alzheimer's Prevention. Resource-savings achieved by adopting an "administer CDR-only-if-QDRS-Global>0" approach were estimated based on 238 subsequent participants. Agreement statistics (concordance = 88.9%) supported use of the QDRS as an initial informant report and modifying center protocol to administer CDRs only when QDRS>0 reduced CDR assessments by 79.8%.
Keywords: Alzheimer’s disease; cognition; memory; neuropsychological test.
Conflict of interest statement
CONFLICT OF INTEREST The authors have no conflict of interest to report.
References
- Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412–2414.
- Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: The InDDEx study. Lancet Neurol 6, 501–512.
- Price JL (1997) Diagnostic criteria for Alzheimer’s disease. Neurobiol Aging 18, S67–S70.
- Hatfield CF, Dudas RB, Dening T (2009) Diagnostic tools for dementia. Maturitas 63, 181–185.
- Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G, (2008) European Task Force G Endpoints for trials in Alzheimer’s disease: A European task force consensus. Lancet Neurol 7, 436–450.
- Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM (2013) Preclinical Alzheimer’s disease and its outcome: A longitudinal cohort study. Lancet Neurol 12, 957–965.
- Galvin JE (2015) The Quick Dementia Rating System (QDRS): A rapid dementia staging tool. Alzheimers Dement (Amst) 1, 249–259.
- Sager MA, Hermann B, La Rue A (2005) Middle-aged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer’s Prevention. J Geriatr Psychiatry Neurol 18, 245–249.
- Moghekar A, Li S, Lu Y, Li M, Wang MC, Albert M, O’Brien R, Team BR (2013) CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 81, 1753–1758.
- Coats M, Morris JC (2005) Antecedent biomarkers of Alzheimer’s disease: The adult children study. J Geriatr Psychiatry Neurol 18, 242–244.
- Koscik RL, La Rue A, Jonaitis EM, Okonkwo OC, Johnson SC, Bendlin BB, Hermann BP, Sager MA (2014) Emergence of mild cognitive impairment in late middle-aged adults in the wisconsin registry for Alzheimer’s prevention. Dement Geriatr Cogn Disord 38, 16–30.
- Clark LR, Koscik RL, Nicholas CR, Okonkwo OC, Engelman CD, Bratzke LC, Hogan KJ, Mueller KD, Bendlin BB, Carlsson CM, Asthana S, Sager MA, Hermann BP, Johnson SC (2016) Mild cognitive impairment in late middle age in the Wisconsin Registry for Alzheimer’s Prevention Study: Prevalence and characteristics using robust and standard neuropsychological normative data. Arch Clin Neuropsychol 31(7), 675–688.
- Jorm AF (1994) A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Development and cross-validation. Psychol Med 24, 145–153.
- Lawton MP, Brody EM Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist (1969) 9, 179–186.
Source: PubMed